- Home
- Publications
- Publication Search
- Publication Details
Title
中期PET-CT在淋巴瘤一线治疗决策中的应用
Authors
Keywords
-
Journal
Journal of Zhejiang University-SCIENCE B
Volume 24, Issue 10, Pages 905-921
Publisher
Zhejiang University Press
Online
2023-10-17
DOI
10.1631/jzus.b2200644
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Guideline for the first‐line management of Classical Hodgkin Lymphoma — A British Society for Haematology guideline
- (2022) George A. Follows et al. BRITISH JOURNAL OF HAEMATOLOGY
- Tumor Flare Reaction in a Classic Hodgkin Lymphoma Patient Treated With Brentuximab Vedotin and Tislelizumab: A Case Report
- (2022) Chunting Zhu et al. Frontiers in Immunology
- PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trial
- (2021) Peter Borchmann et al. LANCET ONCOLOGY
- Optimal timing and criteria of interim PET in DLBCL: a comparative study of 1692 patients
- (2021) J. J. Eertink et al. Blood Advances
- Early Evaluation of Immunotherapy Response in Lymphoma Patients by 18F-FDG PET/CT: A Literature Overview
- (2021) Cristina Ferrari et al. Journal of Personalized Medicine
- Early 18F-FDG PET Flare-up Phenomenon After CAR T-Cell Therapy in Lymphoma
- (2021) Caroline Boursier et al. CLINICAL NUCLEAR MEDICINE
- [18F]FDG PET-CT in patients with DLBCL treated with CAR-T cell therapy: a practical approach of reporting pre- and post-treatment studies
- (2021) Dan Cohen et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- EARLY POSITRON EMISSION TOMOGRAPHY RESPONSE‐ADAPTED TREATMENT IN LOCALIZED DIFFUSE LARGE B‐CELL LYMPHOMA (AAIPI=0) : RESULTS OF THE PHASE 3 LYSA LNH 09‐1B TRIAL
- (2021) S Bologna et al. HEMATOLOGICAL ONCOLOGY
- CALGB 50801 (Alliance): PET adapted therapy in bulky stage I/II classic Hodgkin lymphoma (cHL).
- (2021) Ann S. LaCasce et al. JOURNAL OF CLINICAL ONCOLOGY
- Gonadal Function Recovery in Patients With Advanced Hodgkin Lymphoma Treated With a PET-Adapted Regimen: Prospective Analysis of a Randomized Phase III Trial (AHL2011)
- (2021) Isabelle Demeestere et al. JOURNAL OF CLINICAL ONCOLOGY
- PET-guided eBEACOPP treatment of advanced-stage Hodgkin lymphoma (HD18): follow-up analysis of an international, open-label, randomised, phase 3 trial
- (2021) Stefanie Kreissl et al. Lancet Haematology
- Role of radiotherapy to bulky sites of advanced Hodgkin lymphoma treated with ABVD: final results of FIL HD0801 trial
- (2021) Umberto Ricardi et al. Blood Advances
- Long-Term Follow-up of a PET-Guided Approach to Treatment of Limited-Stage Diffuse Large B-Cell Lymphoma (DLBCL) in British Columbia (BC)
- (2020) Laurie H Sehn et al. BLOOD
- Early experience using salvage radiotherapy for relapsed/refractory non‐Hodgkin lymphomas after CD19 chimeric antigen receptor (CAR) T cell therapy
- (2020) Brandon S. Imber et al. BRITISH JOURNAL OF HAEMATOLOGY
- Consolidation radiotherapy following positron emission tomography complete response in early-stage Hodgkin lymphoma: a meta-analysis
- (2020) Parvez Memet Shaikh et al. LEUKEMIA & LYMPHOMA
- Cost-effectiveness of first-line treatment options for patients with advanced-stage Hodgkin lymphoma: a modelling study
- (2020) Abi Vijenthira et al. Lancet Haematology
- Positron Emission Tomography–Directed Therapy for Patients With Limited-Stage Diffuse Large B-Cell Lymphoma: Results of Intergroup National Clinical Trials Network Study S1001
- (2020) Daniel O. Persky et al. JOURNAL OF CLINICAL ONCOLOGY
- Pembrolizumab followed by AVD in untreated early unfavorable and advanced stage classical Hodgkin lymphoma
- (2020) Pamela Blair Allen et al. BLOOD
- Consolidation Radiotherapy Could Be Safely Omitted in Advanced Hodgkin Lymphoma With Large Nodal Mass in Complete Metabolic Response After ABVD: Final Analysis of the Randomized GITIL/FIL HD0607 Trial
- (2020) Andrea Gallamini et al. JOURNAL OF CLINICAL ONCOLOGY
- Obinutuzumab versus Rituximab in young patients with advanced DLBCL, a PET-guided and randomized phase 3 study by LYSA
- (2020) Steven Le Gouill et al. BLOOD
- The role of PET in the first-line treatment of the most common subtypes of non-Hodgkin lymphoma
- (2020) Sally F Barrington et al. Lancet Haematology
- PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study
- (2019) René-Olivier Casasnovas et al. LANCET ONCOLOGY
- PET-adapted therapy after three cycles of ABVD for all stages of Hodgkin lymphoma: results of the GATLA LH-05 trial
- (2019) Astrid Pavlovsky et al. BRITISH JOURNAL OF HAEMATOLOGY
- Time to prepare for risk adaptation in lymphoma by standardising measurement of metabolic tumour burden
- (2019) Sally F. Barrington et al. JOURNAL OF NUCLEAR MEDICINE
- Five-Year Follow-up of SWOG S0816: Limitations and Values of a PET-Adapted Approach for Stage III/IV Hodgkin Lymphoma
- (2019) Deborah M Stephens et al. BLOOD
- CONSOLIDATION RADIOTHERAPY COULD BE OMITTED IN ADVANCED HODGKIN LYMPHOMA WITH LARGE NODAL MASS IN COMPLETE METABOLIC RESPONSE AFTER ABVD. FINAL ANALYSIS OF THE RANDOMIZED HD0607 TRIAL
- (2019) A. Gallamini et al. HEMATOLOGICAL ONCOLOGY
- Positron Emission Tomography–Guided Treatment in Early-Stage Favorable Hodgkin Lymphoma: Final Results of the International, Randomized Phase III HD16 Trial by the German Hodgkin Study Group
- (2019) Michael Fuchs et al. JOURNAL OF CLINICAL ONCOLOGY
- Prognostic value of baseline metabolic tumor volume in early-stage Hodgkin lymphoma in the standard arm of the H10 trial
- (2018) Anne-Ségolène Cottereau et al. BLOOD
- Interim PET Response-adapted Strategy in Untreated Advanced Stage Hodgkin Lymphoma: Results of GOELAMS LH 2007 Phase 2 Multicentric Trial
- (2018) Sylvain Carras et al. Clinical Lymphoma Myeloma & Leukemia
- Combination of baseline FDG PET/CT total metabolic tumour volume and gene expression profile have a robust predictive value in patients with diffuse large B-cell lymphoma
- (2018) Mathieu Nessim Toledano et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Interim PET-directed therapy in limited stage Hodgkin lymphoma initially treated with ABVD
- (2018) Diego Villa et al. HAEMATOLOGICA
- Positron Emission Tomography–Guided Therapy of Aggressive Non-Hodgkin Lymphomas (PETAL): A Multicenter, Randomized Phase III Trial
- (2018) Ulrich Dührsen et al. JOURNAL OF CLINICAL ONCOLOGY
- PET/CT in Lymphoma: Current Overview and Future Directions
- (2018) Bruce D. Cheson SEMINARS IN NUCLEAR MEDICINE
- Interim PET-directed therapy in limited stage Hodgkin lymphoma initially treated with ABVD
- (2018) Diego Villa et al. HAEMATOLOGICA
- CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET
- (2018) David J. Straus et al. BLOOD
- Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma
- (2018) David M. Kurtz et al. JOURNAL OF CLINICAL ONCOLOGY
- Early positron emission tomography/computed tomography as a predictor of response after CTL019 chimeric antigen receptor –T-cell therapy in B-cell non-Hodgkin lymphomas
- (2018) Nirav N. Shah et al. CYTOTHERAPY
- Early Positron Emission Tomography Response–Adapted Treatment in Stage I and II Hodgkin Lymphoma: Final Results of the Randomized EORTC/LYSA/FIL H10 Trial
- (2017) Marc P.E. André et al. JOURNAL OF CLINICAL ONCOLOGY
- PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group
- (2017) Peter Borchmann et al. LANCET
- Early treatment intensification with R-ICE and 90Y-ibritumomab tiuxetan (Zevalin)-BEAM stem cell transplantation in patients with high-risk diffuse large B-cell lymphoma patients and positive interim PET after 4 cycles of R-CHOP-14
- (2016) Mark Hertzberg et al. HAEMATOLOGICA
- Interim Positron Emission Tomography Response–Adapted Therapy in Advanced-Stage Hodgkin Lymphoma: Final Results of the Phase II Part of the HD0801 Study
- (2016) Pier Luigi Zinzani et al. JOURNAL OF CLINICAL ONCOLOGY
- US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose–Positron Emission Tomography Imaging: Southwest Oncology Group S0816
- (2016) Oliver W. Press et al. JOURNAL OF CLINICAL ONCOLOGY
- Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin’s Lymphoma
- (2016) Peter Johnson et al. NEW ENGLAND JOURNAL OF MEDICINE
- ATLAAS: an automatic decision tree-based learning algorithm for advanced image segmentation in positron emission tomography
- (2016) Beatrice Berthon et al. PHYSICS IN MEDICINE AND BIOLOGY
- Early treatment intensification with R-ICE and 90Y-ibritumomab tiuxetan (Zevalin)-BEAM stem cell transplantation in patients with high-risk diffuse large B-cell lymphoma patients and positive interim PET after 4 cycles of R-CHOP-14
- (2016) Mark Hertzberg et al. HAEMATOLOGICA
- The prognostic value of positron emission tomography performed after two courses (INTERIM-PET) of standard therapy on treatment outcome in early stage Hodgkin lymphoma: A multicentric study by the fondazione italiana linfomi (FIL)
- (2015) Luigi Rigacci et al. AMERICAN JOURNAL OF HEMATOLOGY
- Response-adapted therapy for aggressive non-Hodgkin's lymphomas based on early [18F] FDG-PET scanning: ECOG-ACRIN Cancer Research Group study (E3404)
- (2015) Lode J. Swinnen et al. BRITISH JOURNAL OF HAEMATOLOGY
- Final Results of a Prospective Evaluation of the Predictive Value of Interim Positron Emission Tomography in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP-14 (SAKK 38/07)
- (2015) Christoph Mamot et al. JOURNAL OF CLINICAL ONCOLOGY
- Late Morbidity and Mortality in Patients with Hodgkin's Lymphoma Treated During Adulthood
- (2015) M. J. Matasar et al. JNCI-Journal of the National Cancer Institute
- Results of a Trial of PET-Directed Therapy for Early-Stage Hodgkin’s Lymphoma
- (2015) John Radford et al. NEW ENGLAND JOURNAL OF MEDICINE
- Late Morbidity and Mortality in Patients with Hodgkin's Lymphoma Treated During Adulthood
- (2015) M. J. Matasar et al. JNCI-Journal of the National Cancer Institute
- The prognostic role of post-induction FDG-PET in patients with follicular lymphoma: a subset analysis from the FOLL05 trial of the Fondazione Italiana Linfomi (FIL)
- (2014) S. Luminari et al. ANNALS OF ONCOLOGY
- ABVD (8 cycles) versus BEACOPP (4 escalated cycles ≥4 baseline): final results in stage III–IV low-risk Hodgkin lymphoma (IPS 0–2) of the LYSA H34 randomized trial†
- (2014) N. Mounier et al. ANNALS OF ONCOLOGY
- Intensification treatment based on early FDG-PET in patients with high-risk diffuse large B-cell lymphoma: a phase II GELTAMO trial
- (2014) Emilia Pardal et al. BRITISH JOURNAL OF HAEMATOLOGY
- Interim FDG PET/CT as a prognostic factor in diffuse large B-cell lymphoma
- (2013) Silvia Fuertes et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Results of a prospective phase II trial evaluating interim positron emission tomography-guided high dose therapy for poor prognosis diffuse large B-cell lymphoma
- (2013) Douglas A. Stewart et al. LEUKEMIA & LYMPHOMA
- Interim 18-FDG-PET/CT failed to predict the outcome in diffuse large B-cell lymphoma patients treated at the diagnosis with rituximab-CHOP
- (2012) P. Pregno et al. BLOOD
- Advances in Immuno–Positron Emission Tomography: Antibodies for Molecular Imaging in Oncology
- (2012) Scott M. Knowles et al. JOURNAL OF CLINICAL ONCOLOGY
- Gonadal Function and Fertility in Survivors After Hodgkin Lymphoma Treatment Within the German Hodgkin Study Group HD13 to HD15 Trials
- (2012) Karolin Behringer et al. JOURNAL OF CLINICAL ONCOLOGY
- Eight Cycles of Escalated-Dose BEACOPP Compared With Four Cycles of Escalated-Dose BEACOPP Followed by Four Cycles of Baseline-Dose BEACOPP With or Without Radiotherapy in Patients With Advanced-Stage Hodgkin's Lymphoma: Final Analysis of the HD12 Trial of the German Hodgkin Study Group
- (2011) Peter Borchmann et al. JOURNAL OF CLINICAL ONCOLOGY
- Interim [18F]Fluorodeoxyglucose Positron Emission Tomography Scan in Diffuse Large B-Cell Lymphoma Treated With Anthracycline-Based Chemotherapy Plus Rituximab
- (2011) Violaine Safar et al. JOURNAL OF CLINICAL ONCOLOGY
- 18F-FDG PET/CT for Early Response Assessment in Diffuse Large B-Cell Lymphoma: Poor Predictive Value of International Harmonization Project Interpretation
- (2011) A. F. Cashen et al. JOURNAL OF NUCLEAR MEDICINE
- ABVD versus BEACOPP for Hodgkin's Lymphoma When High-Dose Salvage Is Planned
- (2011) Simonetta Viviani et al. NEW ENGLAND JOURNAL OF MEDICINE
- Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- (2011) J. W. Friedberg Hematology-American Society of Hematology Education Program
- Risk-Adapted Dose-Dense Immunochemotherapy Determined by Interim FDG-PET in Advanced-Stage Diffuse Large B-Cell Lymphoma
- (2010) Craig H. Moskowitz et al. JOURNAL OF CLINICAL ONCOLOGY
- Reduced Treatment Intensity in Patients with Early-Stage Hodgkin's Lymphoma
- (2010) Andreas Engert et al. NEW ENGLAND JOURNAL OF MEDICINE
- High incidence of false-positive PET scans in patients with aggressive non-Hodgkin's lymphoma treated with rituximab-containing regimens
- (2008) H. S. Han et al. ANNALS OF ONCOLOGY
- Assessment of male fertility in patients with Hodgkin's lymphoma treated in the German Hodgkin Study Group (GHSG) clinical trials
- (2008) M. Sieniawski et al. ANNALS OF ONCOLOGY
- Response assessment after an inductive CHOP or CHOP-like regimen with or without rituximab in 103 patients with diffuse large B-cell lymphoma: integrating 18fluorodeoxyglucose positron emission tomography to the International Workshop Criteria
- (2008) J. Dupuis et al. ANNALS OF ONCOLOGY
- Overview of Lymphoma Diagnosis and Management
- (2008) Matthew J. Matasar et al. RADIOLOGIC CLINICS OF NORTH AMERICA
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started